Extract Labs Launches Immune Support Tincture, First CBGa Product to Hit the Consumer Market

Extract Labs’ Immune Support Tincture is the first consumer product to contain CBGa. Other tinctures on the market only have traces of CBGa and CBDa, while the difference may seem minor, CBD and CBG are totally different molecules than their acidic precursors. CBGa and CBDa are considerably rarer as most extraction and refinement processes require heat to perform them efficiently. The heat will often cause CBDa and CBGa to convert over to CBD and CBG respectively – converting the cannabinoids at a molecular level. Extract Labs’ in-house team of expert scientists has successfully developed a proprietary method for processing these delicate cannabinoids and formulate them into a tincture that is rich in CBGa, CBDa, CBG, and CBD.

“Extract Labs is proud to be the first-to-market with a cannabinoid blend of this caliber. We are launching the Immune Support Tincture at a critical time where research continues to show that cannabis compounds, including CBGa and CBDa, have significant effects on supporting the prevention of COVID infection,” said Craig Henderson, CEO and founder of Extract Labs. “Extract Labs is at the forefront of hemp-derived product innovation and this launch solidifies our status as a dominant player in the CBD industry and overall health and wellness space.”

Extracted from Colorado-grown hemp, this the Immune Support Tincture will come in a 30ml bottle containing 2,000mg full-spectrum cannabinoids. Lab tested for purity, each serving contains 17mg CBGa, 17mg CBDa, 17mg CBG and 17mg CBD. The blend of raw hemp extracts used to formulate the tincture also ensure that the product is totally natural.